Table 2.

Response at end of treatment with rituximab combined with liposomal doxorubicin in 17 patients with symptomatic KSHV-MCD

NCI-KSHV-MCD Response Criteria
Response category	Response	n(%)
Clinical response	Complete response	15 (88)
	Symptom-free disease	1 (6)
	Progressive disease§	1 (6)
	Major clinical response*	16 (94)
Biochemical response	Complete response	13 (76)
	Partial response	2 (12)
	Major biochemical response†	15 (88)
	Stable disease	1 (6)
	Progressive disease§	1 (6)
Radiographic response	Complete response
	Nodes	13 (76)
	Spleen	8 (47)
	Partial response
	Nodes	4 (24)
	Spleen	7 (41)
	Major radiographic response‡	15 (88)
	Stable disease (spleen)	1 (6)
	Progressive disease§ (spleen)	1 (6)
Overall response	Complete response	5 (29)
	Partial response	9 (53)
	Stable disease	2 (12)
	Progressive disease§	1 (6)
KSHV-MCD Clinical Benefic Criteria	Complete response	14 (82)
	Partial response	1 (6)
	Stable disease	1 (6)
	Progressive disease	1 (6)

^*Major clinical response = complete response + symptom-free disease + partial response.

^†Major biochemical response = complete response + partial response.

^‡Major radiographic response = at least complete response or partial response by both lymph nodes and spleen criteria.

^§One patient was not evaluable radiographically.